JINGXIN(SZ:002020) Xin Lang Cai Jing·2025-11-19 01:51Core Viewpoint - Jingxin Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 64.25% and a recent decline of 2.01% on November 19, 2023 [1] Financial Performance - For the period from January to September 2025, Jingxin Pharmaceutical reported revenue of 3.048 billion yuan, a year-on-year decrease of 5.00%, while net profit attributable to shareholders was 576 million yuan, reflecting a slight increase of 0.10% [2] - The company has cumulatively distributed 2.11 billion yuan in dividends since its A-share listing, with 801 million yuan distributed over the past three years [3] Stock Market Activity - As of November 19, 2023, Jingxin Pharmaceutical's stock price was 20.48 yuan per share, with a total market capitalization of 17.634 billion yuan [1] - The stock has seen significant trading activity, with a net outflow of 1.6599 million yuan from main funds and a notable presence on the "Dragon and Tiger List" on July 4, 2023, where it recorded a net purchase of 1.11 billion yuan [1] Shareholder Information - As of September 30, 2025, the number of shareholders for Jingxin Pharmaceutical was 22,300, a decrease of 13.08% from the previous period, while the average circulating shares per person increased by 15.05% to 32,438 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 7.4588 million shares, a decrease of 2.1904 million shares compared to the previous period [3] Business Overview - Jingxin Pharmaceutical, established on February 13, 1999, and listed on July 15, 2004, specializes in the research, production, and sales of chemical preparations, traditional Chinese medicine, biological preparations, chemical raw materials, and medical devices [1] - The company's main business revenue composition is 82.46% from pharmaceutical manufacturing and 17.54% from medical devices [1]